{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:50:42Z","timestamp":1789941042275,"version":"4.0.1"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0134707","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T17:50:01Z","timestamp":1439315401000},"page":"e0134707","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action"],"prefix":"10.1371","volume":"10","author":[{"given":"Philippe A.","family":"Gallay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayan","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Trepanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Ure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosme","family":"Ordonez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11904-010-0071-3","article-title":"HIV\/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies","volume":"8","author":"EA Operskalski","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref2","first-page":"289","article-title":"Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003","volume":"88","author":"J Coste","year":"2005","journal-title":"Vox Sang"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIV-Infected Person","volume":"138","author":"MS Sulkowski","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2105\/AJPH.86.5.655","article-title":"Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses","volume":"86","author":"RS Garfein","year":"1996","journal-title":"Am J Public Health"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ije\/dyh019","article-title":"Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China","volume":"33","author":"RJ Garten","year":"2004","journal-title":"Int J Epidemiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09540120802017610","article-title":"Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study","volume":"21","author":"VM Quan","year":"2009","journal-title":"AIDS Care"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV coinfection","volume":"44","author":"MJ Alter","year":"2006","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","article-title":"Correlates of hepatitis C virus infections among injection drug users","volume":"74","author":"DL Thomas","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/JCM.35.12.3274-3277.1997","article-title":"Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland","volume":"35","author":"SA Villano","year":"1997","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1360-0443.2009.02827.x","article-title":"Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population based cohort study","volume":"105","author":"MV Larsen","year":"2010","journal-title":"Addiction"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","article-title":"HIV\/hepatitis C coinfection natural history and disease progression","volume":"6","author":"MD Hernandez","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV\u2014a one-two punch","volume":"137","author":"AY Kim","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"ref13","first-page":"S48","article-title":"HCV and HIV: a tale of two viruses","volume":"4","author":"KE Sherman","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/QAD.0b013e3283454174","article-title":"The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients","volume":"25","author":"M L\u00f3pez-Di\u00e9guez","year":"2011","journal-title":"AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2334-10-303","article-title":"The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006\u20132010","volume":"10","author":"MA Loko","year":"2010","journal-title":"BMC Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"HH Thein","year":"2008","journal-title":"AIDS"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23679","article-title":"Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV\/hepatitis C virus-induced liver fibrosis","volume":"52","author":"AC Tuyama","year":"2010","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAI.0b013e31815d2f59","article-title":"Risk of hepatitis-related mortality increased among hepatitis C virus\/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study","volume":"47","author":"C Smit","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/500843","article-title":"Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV\/HIV-coinfected women: role of HCV on expression of primed\/memory T cells","volume":"193","author":"L Al-Harthi","year":"2006","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/372359a0","article-title":"Specific incorporation of cyclophilin A into HIV-1 virions","volume":"372","author":"EK Franke","year":"1994","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/372363a0","article-title":"Functional association of cyclophilin A with HIV-1 virions","volume":"372","author":"M Thali","year":"1994","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/AAC.38.8.1763","article-title":"Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog","volume":"38","author":"B Rosenwirth","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm910","article-title":"Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors","volume":"9","author":"GJ Towers","year":"2003","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coviro.2013.11.003","article-title":"A model for cofactor use during HIV-1 reverse transcription and nuclear entry","volume":"4","author":"L Hilditch","year":"2014","journal-title":"Curr Opin Virol"},{"key":"ref25","article-title":"The role of immunophilins in viral infection","author":"S Hopkins","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"K Watashi","year":"2003","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","article-title":"Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins","volume":"129","author":"M Nakagawa","year":"2005","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.00310-06","article-title":"NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon","volume":"50","author":"S Ma","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","article-title":"Diverse effects of cyclosporine on hepatitis C virus strain replication","volume":"80","author":"N Ishii","year":"2006","journal-title":"J Virol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"K Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro","volume":"43","author":"J Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"F Yang","year":"2008","journal-title":"J Virol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.22131","article-title":"The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus","volume":"47","author":"R Flisiak","year":"2008","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-na\u00efve hepatitis C patients","volume":"49","author":"R Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"A Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"U Chatterji","year":"2009","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Z Liu","year":"2009","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2009.10.043","article-title":"Multiple cyclophilins involved in different cellular pathways mediate HCV replication","volume":"397","author":"LA Gaither","year":"2010","journal-title":"Virology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/v2081621","article-title":"Cyclophilin inhibitors as a novel HCV therapy","volume":"2","author":"H Tang","year":"2010","journal-title":"Viruses"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","article-title":"The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection","volume":"57","author":"S Hopkins","year":"2012","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"M Dorner","year":"2013","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2014.07.008","article-title":"Cyclophilin inhibition as potential therapy for liver diseases","volume":"61","author":"NV Naoumov","year":"2014","journal-title":"J Hepatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/jm500223x","article-title":"From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds","volume":"57","author":"ZK Sweeney","year":"2014","journal-title":"J Med Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2014.10.023","article-title":"Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection","volume":"22","author":"MJ Hansson","year":"2015","journal-title":"Chem Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1073\/pnas.0801388105","article-title":"Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus","volume":"105","author":"MD Bobardt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"J Zhong","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e88866","DOI":"10.1371\/journal.pone.0088866","article-title":"HCV core residues critical for infectivity are also involved in core-NS5A complex formation","volume":"9","author":"K Gawlik","year":"2014","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"T Wakita","year":"2005","journal-title":"Nat Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"JM Vrolijk","year":"2003","journal-title":"J Virol Methods"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"G Koutsoudakis","year":"2006","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"11241","DOI":"10.1073\/pnas.88.24.11241","article-title":"Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture","volume":"88","author":"D Richman","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0042-6822(95)80069-7","article-title":"Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31\u20138959","volume":"206","author":"H Jacobsen","year":"1995","journal-title":"Virology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"40293","DOI":"10.1074\/jbc.M506314200","article-title":"Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells","volume":"280","author":"U Chatterji","year":"2005","journal-title":"J Biol Chem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"U Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"U Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0167-4838(84)90285-1","article-title":"Conformational specificity of chymotrypsin toward proline-containing substrates","volume":"791","author":"G Fischer","year":"1984","journal-title":"Biochim Biophys Acta"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/bi00239a007","article-title":"Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay","volume":"30","author":"JL Kofron","year":"1991","journal-title":"Biochemistry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.01324-07","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent","volume":"52","author":"RG Ptak","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes","volume":"56","author":"S Hopkins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref60","article-title":"Cyclophilin and NS5A Inhibitors, but not other Anti-HCV Agents, Preclude HCV-Mediated Formation of Double Membrane Vesicle Viral Factories","author":"U Chatterji","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e26300","DOI":"10.1371\/journal.pone.0026300","article-title":"The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement","volume":"6","author":"AW Tai","year":"2011","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"JA Garcia-Rivera","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e1001118","DOI":"10.1371\/journal.ppat.1001118","article-title":"A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach","volume":"6","author":"F Yang","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/v4123303","article-title":"Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus","volume":"4","author":"IU Ansari","year":"2012","journal-title":"Viruses"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1128\/JVI.06641-11","article-title":"A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility","volume":"86","author":"H Gris\u00e9","year":"2012","journal-title":"J Virol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.virol.2012.11.018","article-title":"Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility","volume":"436","author":"IU Ansari","year":"2013","journal-title":"Virology"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1128\/JVI.77.9.5487-5492.2003","article-title":"Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons","volume":"77","author":"R Gosert","year":"2003","journal-title":"J Virol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1128\/JVI.00640-08","article-title":"A dynamic view of hepatitis C virus replication complexes","volume":"82","author":"B W\u00f6lk","year":"2008","journal-title":"J Virol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"e1003056","DOI":"10.1371\/journal.ppat.1003056","article-title":"Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"I Romero-Brey","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1128\/JVI.01370-13","article-title":"Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment","volume":"87","author":"D Paul","year":"2013","journal-title":"J Virol"},{"key":"ref71","article-title":"Inhibition of HCV Replication by Cyclophilin Antagonists is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation","author":"V Madan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"C Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.4049\/jimmunol.174.10.6030","article-title":"Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine","volume":"174","author":"J Colgan","year":"2005","journal-title":"J Immunol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/emboj\/20.6.1300","article-title":"Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells","volume":"20","author":"D Braaten","year":"2001","journal-title":"EMBO J"},{"key":"ref75","article-title":"Nuclear architecture dictates HIV-1 integration site selection","author":"B Marini","year":"2015","journal-title":"Nature"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"K Lin","year":"2013","journal-title":"Antiviral Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.antiviral.2013.09.020","article-title":"Host-targeting agents in the treatment of hepatitis C: a beginning and an end?","volume":"100","author":"JM Baugh","year":"2013","journal-title":"Antiviral Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0134707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T02:53:25Z","timestamp":1599447205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0134707"}},"subtitle":[],"editor":[{"given":"Gulam","family":"Waris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":77,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0134707","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}